- Home
- EQ vs ECDA Comparison
EQ vs ECDA Comparison
Compare EQ & ECDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- ECDA
- Stock Information
- Founded
- EQ 2017
- ECDA 2013
- Country
- EQ United States
- ECDA United States
- Employees
- EQ N/A
- ECDA N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- ECDA Auto Manufacturing
- Sector
- EQ Health Care
- ECDA Consumer Discretionary
- Exchange
- EQ Nasdaq
- ECDA Nasdaq
- Market Cap
- EQ 31.1M
- ECDA 34.8M
- IPO Year
- EQ 2018
- ECDA N/A
- Fundamental
- Price
- EQ $0.88
- ECDA $0.84
- Analyst Decision
- EQ Buy
- ECDA
- Analyst Count
- EQ 2
- ECDA 0
- Target Price
- EQ $5.00
- ECDA N/A
- AVG Volume (30 Days)
- EQ 2.2M
- ECDA 33.9K
- Earning Date
- EQ 03-24-2025
- ECDA 03-04-2025
- Dividend Yield
- EQ N/A
- ECDA N/A
- EPS Growth
- EQ N/A
- ECDA N/A
- EPS
- EQ N/A
- ECDA N/A
- Revenue
- EQ $45,914,000.00
- ECDA $25,728,409.00
- Revenue This Year
- EQ $4.77
- ECDA $125.56
- Revenue Next Year
- EQ N/A
- ECDA $36.05
- P/E Ratio
- EQ N/A
- ECDA N/A
- Revenue Growth
- EQ 7.70
- ECDA 123.27
- 52 Week Low
- EQ $0.49
- ECDA $0.75
- 52 Week High
- EQ $3.25
- ECDA $1.55
- Technical
- Relative Strength Index (RSI)
- EQ 58.42
- ECDA 45.31
- Support Level
- EQ $0.85
- ECDA $0.82
- Resistance Level
- EQ $0.98
- ECDA $0.95
- Average True Range (ATR)
- EQ 0.10
- ECDA 0.08
- MACD
- EQ 0.01
- ECDA 0.00
- Stochastic Oscillator
- EQ 62.50
- ECDA 41.54
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About ECDA ECD Automotive Design Inc.
ECD Automotive Design Inc is a custom-car builder in the Restomod sector with a focus on British classic motor vehicles of various models of both two-door and four-door styles. The company has established a facility geared towards producing the most customized Land Rovers with the highest quality of parts and the highest quality labor force building each vehicle. ECD restores Land Rovers Defenders, Land Rover Series IIA, the Range Rover Classic and the Jaguar E-Type. It upgrade any engine, including Chevrolet V8's, Land Rover V8's, Cummins diesel engines and new electric drivetrains, performing all the necessary body work, drivetrain selection and installation, every stitch in the interior, paint work, up to placement of the last nut and bolt.